<DOC>
	<DOCNO>NCT03040141</DOCNO>
	<brief_summary>This study compare efficacy safety VIS410 combination oseltamivir vs oseltamivir alone severely ill subject influenza A infection require oxygen support .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Intravenous VIS410 Addition Oseltamivir ( Tamiflu® ) Compared With Oseltamivir Alone Hospitalized Adults With Influenza A Infection Requiring Oxygen Support</brief_title>
	<detailed_description>This study compare efficacy safety VIS410 combination oseltamivir vs oseltamivir alone severely ill subject influenza A infection require oxygen support . Subjects follow 56 day .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Male female subject age ≥ 18 year . Test positive influenza A rapid antigen test another commercially available test adequate nasopharyngeal specimen accordance manufacturer 's instruction , acceptable local test , include PCR , FIA , ELISA Onset influenza symptom 5 day VIS410/placebo infusion ; symptom may include cough , dyspnea , sore throat , fever , myalgia , headache , nasal symptom ( rhinorrhea , congestion ) , fatigue , diarrhea , anorexia , nausea , vomit . Need supplemental oxygen least 40 % ( 4 L/min ) and/or hypoxemia define SpO2 le 90 % Women childbearing potential must negative pregnancy test within 2 day prior VIS410/placebo infusion . Women fulfill one follow criterion : Postmenopausal ; either amenorrhea ≥ 12 month follicle stimulate hormone &gt; 40 mIU/mL document medical history Surgically sterile ; hysterectomy , bilateral oophorectomy , tubal ligation Women childbearing potential participate heterosexual sexual relation must willing use adequate contraception screen 60 day post VIS410/placebo infusion . Nonvasectomized ( vasectomize less 6 month prior dose ) male subject female partner childbearing potential must use effective birth control method screen 60 day post VIS410/placebo infusion . Subject , legally authorize representative ( LAR ) , able understand purpose risk study willing give voluntary write informed consent . Known suspected intolerance hypersensitivity VIS410 , oseltamivir , pretreatment medication ( diphenhydramine , ibuprofen acetylsalicylic acid [ ASA ] ) , closely related compound ( eg , monoclonal antibody ) History receive monoclonal antibody product ( include VIS410 ) within 3 month prior VIS410/placebo dose plan administration study period Subjects take 6 dos approve antiviral therapy influenza within prior 96 hour ( eg , oral oseltamivir , inhaled zanamivir , IV peramivir , oral ribavirin ) onset symptom VIS410/placebo dose Subjects lung transplant history severe chronic lung disease condition require &gt; 2 L/minute home oxygen therapy ( ie , severe chronic obstructive pulmonary disease [ COPD ] , pulmonary fibrosis ) Subjects extracorporeal membrane oxygenation ( ECMO ) time randomization Subjects active graftvshost disease , hematopoietic stem cell transplant within previous 90 day , human immunodeficiency virus infection CD4 cell count le 200 per cubic millimeter Hospitalization &gt; 48 hour prior randomization High probability mortality within 48 hour randomization determine Investigator Subjects weigh less 45 kg Enrollment investigational drug device study , disease vaccine study within 30 day prior Day 1 within 5 halflives investigational compound , whichever long Known suspect alcohol drug abuse , , abuse level would compromise safety cooperation subject opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>